Q3 FY2026 · ended Sep 27, 2026 · Revenue $16.58B, -0.4% YoY · Filed Nov 3, 2026
Pfizer Inc (PFE) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 27, 2026, it reported revenue of $16.6 billion and net income of $3.2 billion. Free cash flow was $4.8 billion. As of Sep 27, 2026 it held $10.9 billion in cash and investments and $62.6 billion in total debt.
Revenue
$16.58B
-0.4% vs year-ago quarter
Net income
$3.24B
-8.4% vs year-ago quarter
Operating cash flow
$5.38B
+16.8% vs year-ago quarter
Free cash flow
$4.80B
+20.0% vs year-ago quarter
EPS
$0.56
-9.7% vs year-ago quarter
Dividend per share
$0.00
Shares outstanding
5.70B
+0.2% vs year-ago quarter
Net cash
$-51.66B
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PFE (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 78003
- Former names
- PFIZER INC (until Nov 3, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 27, 2026 |
Q2 FY2026 Jun 28, 2026 |
Q1 FY2026 Mar 29, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 28, 2025 |
|---|---|---|---|---|---|
| Revenue | $16.6B | $15.0B | $14.5B | $17.6B | $16.7B |
| Net income | $3.2B | -$248.0M | $2.7B | -$1.6B | $3.5B |
| Diluted EPS | $0.56 | -$0.04 | $0.47 | -$0.29 | $0.62 |
| Operating cash flow | $5.4B | $835.0M | $2.6B | $5.3B | $4.6B |
| Free cash flow | $4.8B | $302.0M | $2.2B | $4.5B | $4.0B |
| Total assets | $204.5B | $201.1B | $207.6B | $208.2B | $208.7B |
| Total liabilities | $115.2B | $115.6B | $117.2B | $121.4B | $115.6B |
| Stockholders' equity | $89.0B | $85.2B | $90.1B | $86.5B | $92.8B |
| Cash and investments | $10.9B | $8.3B | $9.9B | $10.3B | $11.5B |
| Total debt | $62.6B | $63.1B | $64.4B | $67.3B | $61.7B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Nov 3, 2026 | Oct 30, 2026 |
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 27, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 28, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 18, 2026 | Jun 18, 2026 |
All 1000 Pfizer Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.